Sanofi–Translate Bio COVID-19 vaccine
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | MRT5500, VAW00001 |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Sanofi–Translate Bio COVID-19 vaccine also known as MRT5500 or VAW00001 is a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[1][2]
Deployment[edit]
Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership.[3]
References[edit]
- ^ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Retrieved 20 March 2021.
- ^ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.
- ^ Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans, 23 June 2020, retrieved 7 August 2020
External links[edit]
 |
Scholia has a profile for Sanofi–Translate Bio COVID-19 vaccine (Q106514952). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |